387 related articles for article (PubMed ID: 17594390)
1. Pioglitazone and sulfonylureas: effectively treating type 2 diabetes.
Hanefeld M
Int J Clin Pract Suppl; 2007 Jun; 61(153):20-7. PubMed ID: 17594390
[TBL] [Abstract][Full Text] [Related]
2. The importance of beta-cell management in type 2 diabetes.
Standl E
Int J Clin Pract Suppl; 2007 Jun; (153):10-9. PubMed ID: 17594389
[TBL] [Abstract][Full Text] [Related]
3. beta-cell function and anti-diabetic pharmacotherapy.
Del Prato S; Bianchi C; Marchetti P
Diabetes Metab Res Rev; 2007 Oct; 23(7):518-27. PubMed ID: 17883249
[TBL] [Abstract][Full Text] [Related]
4. Pioglitazone plus glimepiride: a promising alternative in metabolic control.
Derosa G
Int J Clin Pract Suppl; 2007 Jun; (153):28-36. PubMed ID: 17594391
[TBL] [Abstract][Full Text] [Related]
5. Metformin and pioglitazone: Effectively treating insulin resistance.
Staels B
Curr Med Res Opin; 2006; 22 Suppl 2():S27-37. PubMed ID: 16914073
[TBL] [Abstract][Full Text] [Related]
6. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
Standl E; Schnell O
Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
[No Abstract] [Full Text] [Related]
7. Glucolipotoxicity and beta cells in type 2 diabetes mellitus: target for durable therapy?
van Raalte DH; Diamant M
Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S37-46. PubMed ID: 21864750
[TBL] [Abstract][Full Text] [Related]
8. Why insulin sensitizers but not secretagogues should be retained when initiating insulin in type 2 diabetes.
Raskin P
Diabetes Metab Res Rev; 2008; 24(1):3-13. PubMed ID: 17968971
[TBL] [Abstract][Full Text] [Related]
9. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
Monami M; Vitale V; Ambrosio ML; Bartoli N; Toffanello G; Ragghianti B; Monami F; Marchionni N; Mannucci E
Adv Ther; 2012 Sep; 29(9):736-46. PubMed ID: 22923161
[TBL] [Abstract][Full Text] [Related]
10. Effects of thiazolidinediones and sulfonylureas in patients with diabetes.
Derosa G; Maffioli P
Diabetes Technol Ther; 2010 Jun; 12(6):491-501. PubMed ID: 20470234
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy using metformin or thiazolidinediones and insulin in the treatment of diabetes mellitus.
Strowig SM; Raskin P
Diabetes Obes Metab; 2005 Nov; 7(6):633-41. PubMed ID: 16219007
[TBL] [Abstract][Full Text] [Related]
12. Management of type 2 diabetes mellitus. Role of thiazolidinediones.
Noble J; Baerlocher MO; Silverberg J
Can Fam Physician; 2005 May; 51(5):683-7. PubMed ID: 15934272
[TBL] [Abstract][Full Text] [Related]
13. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
Defronzo RA; Mehta RJ; Schnure JJ
Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
[TBL] [Abstract][Full Text] [Related]
14. Oral combination therapy with thiazolidinediones and sulfonylureas in type 2 diabetes.
Charbonnel B
Int J Clin Pract Suppl; 2007 Jun; (153):1-2. PubMed ID: 17594387
[No Abstract] [Full Text] [Related]
15. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
Hemmingsen B; Lund SS; Vaag A
Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
[TBL] [Abstract][Full Text] [Related]
16. Effects of one year treatment of vildagliptin added to pioglitazone or glimepiride in poorly controlled type 2 diabetic patients.
Derosa G; Maffioli P; Ferrari I; Mereu R; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Salvadeo SA
Horm Metab Res; 2010 Aug; 42(9):663-9. PubMed ID: 20560108
[TBL] [Abstract][Full Text] [Related]
17. Limitations of the HOMA-B score for assessment of beta-cell functionality in interventional trials-results from the PIOglim study.
Pfützner A; Derwahl M; Jacob S; Hohberg C; Blümner E; Lehmann U; Fuchs W; Forst T
Diabetes Technol Ther; 2010 Aug; 12(8):599-604. PubMed ID: 20615100
[TBL] [Abstract][Full Text] [Related]
18. Promising new approaches.
Reasner CA
Diabetes Obes Metab; 1999 May; 1 Suppl 1():S41-8. PubMed ID: 11220287
[TBL] [Abstract][Full Text] [Related]
19. The role of glimepiride in the effective management of Type 2 diabetes.
Davis SN
J Diabetes Complications; 2004; 18(6):367-76. PubMed ID: 15531188
[TBL] [Abstract][Full Text] [Related]
20. [Warning signals insulin resistance. Insulin resistance causes not only diabetes].
MMW Fortschr Med; 2004 Jul; 146(29-30):49. PubMed ID: 15540564
[No Abstract] [Full Text] [Related]
[Next] [New Search]